Prospective Phase II Trial of [⁶⁸Ga]Ga-NODAGA-E[c(RGDyK)]₂ PET/CT Imaging of Integrin α_vβ₃ for Prognostication in Patients with Neuroendocrine Neoplasms.

ABSTRACT: Integrin α_vβ₃, a subtype of the arginine-glycine-aspartate (RGD)-recognizing cell surface integrins, is upregulated on endothelial cells during angiogenesis and on tumor cells. Because of involvement in tumor growth, invasiveness and metastases, and angiogenesis, integrin α_vβ₃ is an attractive target in cancers. In this study, we applied ⁶⁸Ga-NODAGA-E[c(RGDyK)]₂ for imaging of integrin α_vβ₃ in patients with neuroendocrine neoplasms (NENs) and its potential use for prognostication. We hypothesized that ⁶⁸Ga-NODAGA-E[c(RGDyK)]₂ PET/CT would show tumor lesion uptake and that higher tumor lesion uptake was associated with a poorer prognosis. Methods: Between December 2017 and No

SUBMITTER: Carlsen EA 

PROVIDER: S-EPMC9902862 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature